The arrival of a 750mcg teriparatide injection in Australia has been cautiously managed, with distribution primarily through specialist endocrinologists and designated clinics . Early market uptake for this concentrated formulation remain confidential from the manufacturer , although industry sources suggest moderate adoption rates . Patient access